| Dr Prayag S Patel, MD | |
|
450 Clarkson Ave, Box 1262, Brooklyn, NY 11203-2012 | |
| (718) 270-1638 | |
| Not Available |
| Full Name | Dr Prayag S Patel |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Location | 450 Clarkson Ave, Brooklyn, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619322971 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 316571 (New York) | Primary |
| Entity Name | Maimonides Faculty Practice Plan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053344846 PECOS PAC ID: 7012808348 Enrollment ID: O20040324000597 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Modern scientific understanding has considered multiple sclerosis (MS) to be a disease controlled by the T cell, a type of white blood cell. Research has shown that in MS, T cells inappropriately attack myelin, the protective layer of fat covering nerves in the central nervous system, exposing them to damage.
Today, Healthcare Information and Management Systems Society and AVIA announced HX360, a new co-developed initiative. HX360 was created to improve the way that health care is delivered by both inspiring and facilitating the adoption and use of next generation (non-EHR Platform) technologies by provider organizations, in areas where health system executives are passionate to combine the right mix of resources, processes and technologies.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
Senesco Technologies, Inc., announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
› Verified 7 days ago
| Entity Name | Maimonides Medical Center Division Of Otolaryngology Fpp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164608501 PECOS PAC ID: 3870677594 Enrollment ID: O20080219000831 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Modern scientific understanding has considered multiple sclerosis (MS) to be a disease controlled by the T cell, a type of white blood cell. Research has shown that in MS, T cells inappropriately attack myelin, the protective layer of fat covering nerves in the central nervous system, exposing them to damage.
Today, Healthcare Information and Management Systems Society and AVIA announced HX360, a new co-developed initiative. HX360 was created to improve the way that health care is delivered by both inspiring and facilitating the adoption and use of next generation (non-EHR Platform) technologies by provider organizations, in areas where health system executives are passionate to combine the right mix of resources, processes and technologies.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
Senesco Technologies, Inc., announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Prayag S Patel, MD 450 Clarkson Ave, Box 1262, Brooklyn, NY 11203-2012 Ph: (718) 270-8867 | Dr Prayag S Patel, MD 450 Clarkson Ave, Box 1262, Brooklyn, NY 11203-2012 Ph: (718) 270-1638 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Modern scientific understanding has considered multiple sclerosis (MS) to be a disease controlled by the T cell, a type of white blood cell. Research has shown that in MS, T cells inappropriately attack myelin, the protective layer of fat covering nerves in the central nervous system, exposing them to damage.
Today, Healthcare Information and Management Systems Society and AVIA announced HX360, a new co-developed initiative. HX360 was created to improve the way that health care is delivered by both inspiring and facilitating the adoption and use of next generation (non-EHR Platform) technologies by provider organizations, in areas where health system executives are passionate to combine the right mix of resources, processes and technologies.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
Senesco Technologies, Inc., announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
› Verified 7 days ago
Anthony Paul Vastola, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 300 Cadman Plz W, Suite 1301, Brooklyn, NY 11201 Phone: 929-252-1566 Fax: 718-208-4663 | |
Harry Pantelides, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 170 Broadway, Brooklyn, NY 11211 Phone: 718-618-9181 | |
Dr. Marc David Gottlieb, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6740 4th Ave Fl 3, Brooklyn, NY 11220 Phone: 929-455-2700 | |
Dr. Sara Abu Ghanem, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 450 Clarkson Ave # Msc126, Brooklyn, NY 11203 Phone: 718-270-1638 Fax: 718-270-3924 | |
Dr. Mayer Adler, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6910 Bay Parkway, Brooklyn, NY 11204 Phone: 718-236-3900 Fax: 718-236-8787 | |
Dr. Ofer Azoulay, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 185 Montague St Fl 5, Brooklyn, NY 11201 Phone: 929-284-6120 | |
Simon H Friedman, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1636 East 14th Str, Suite 120, Brooklyn, NY 11229 Phone: 718-339-2300 Fax: 718-998-8020 |